These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2033963)

  • 21. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
    Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.
    Morrison FS; Kopecky KJ; Head DR; Athens JW; Balcerzak SP; Gumbart C; Dabich L; Costanzi JJ; Coltman CA; Saiki JH
    Leukemia; 1992 Jul; 6(7):708-14. PubMed ID: 1625490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
    Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
    J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.
    Todeschini G; Meneghini V; Pizzolo G; Cassibba V; Ambrosetti A; Veneri D; Nadali G; Zanotti R; Tecchio C; Perona G
    Leukemia; 1994 Mar; 8(3):376-81. PubMed ID: 8127142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
    Stock W; Johnson JL; Stone RM; Kolitz JE; Powell BL; Wetzler M; Westervelt P; Marcucci G; DeAngelo DJ; Vardiman JW; McDonnell D; Mrózek K; Bloomfield CD; Larson RA
    Cancer; 2013 Jan; 119(1):90-8. PubMed ID: 22744771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia.
    Ribeiro RC; Rivera GK; Hudson M; Mulhern RK; Hancock ML; Kun L; Mahmoud H; Sandlund JT; Crist WM; Pui CH
    J Clin Oncol; 1995 Feb; 13(2):333-8. PubMed ID: 7844594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
    Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
    J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
    Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
    J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
    Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
    Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
    Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
    Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
    Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
    Todeschini G; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Zanotti R; Ricetti MM; Solero P; April F; Perona G
    Leukemia; 1998 Feb; 12(2):144-9. PubMed ID: 9519775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
    Escherich G; Zimmermann M; Janka-Schaub G;
    Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.